12-肺部给药新剂型-吸入粉雾剂

-300410[]10-[]8090122PfeifferValois1999Pfeiffer1.aerosolofmicropowdersforinspiration[1]2.DNase[2][3]103.[4],Borgstrom142[5]4.4.1FDA[6-14][1115]--[16]Vanderbist[6]-Nacystelyn6310090125100160m100160mC1arke[10]4.20.57m4.2.123m4.2.2CO2Hartwig[17]Yeo[18]904m101m4.2.3[19]L167m909949m9648658m[20]4.3[21](1)(2)(3)(4)(5)()Cassidy[22]1050-208-13-549-41Bennett[23][24][25-26]Maa[27]504.420[28-30]RotahalerDiskusSpirosTurbuhalerOrioninhalereasyhalerspiros20013spiros3016()8095[31]5.FDA[28][32][33][][1]..2003194-195[2]-[J]199627(9):404-407[3]RuijgrokEJVultoAGVanEttenEWMAeroso1deliveryofamphotericinBdesoxycho1ate(Fungizone)andliposomalamphotericinB(AmBisome)aeroso1characteristicsandinvivoamphotericinBdepositioninRats[J]JPharmacol200052(6)619-627[4]GandertonDKassemNMGandertonDetalAdvancesinPharmaceuticalSciences[M].Vol6.LondonAcademicPress1992.165-191[5]BorgstromLNewmanSWeiszAetal.PulmonarydepositionofinhaledterbulalinecomparisonofscanninggammacameraandurinaryexcretionmethodsJPharmSci,l992;8l(8)753755[6]VanderbistFweryBMoyano-PavonIetal.Optimizationofadrypowderinhalerformulationofnacystelyn,anewmucoactiveagent[J]JPharmPharmacol,199951(11)12291234[7]SteckelHMuellerBW.InvitroevaluationofdrypowderinhalersIIinfluenceofcarrerparticlesizeandconcentrationoninvitrodeposition[J]IntJPharm1997154(1)3137[8]LarhribHZengXMMartinGPetal.Theuseofdifferentgradesoflactoseasacarrierforaeroso1isedsalbutamolsulphate[J]IntJPharm1999191(1)114[9]ZengXMPandhalKHMartinGP.Theinfluenceoflactosecarrieronthecontenthomogeneityanddispersibiltyofbeclomethasonedipropionatefromdrypowderaeroso1s[J]IntJPharm2000197(12)4152[10]C1arkeMJTobynMJStaniforlthJNTheformulationofpowderinhalationsystemscontainingahighmassofnedocromi1sodiumtrihydate[J].JPharmSci200190(2)213223[11]BosquillonCLombryCPreatVetalInfluenceofformulationexcipientsandphysicalcharacteristicsofinhalationdrypowdersontheiraeroso1izationperformance[J]JControlledRelease,200170(3)329339[12]LoueyMDMulvaneyPStewartPJCharacterisationofadhesionalpropertiesoflactosecarriersusingatomicforcemicroscopy[J]JPharmBiomedAnal200125(34)559567[13]KarhuMKuikkaKauppinenTetalPulmonarydepositionoflactosecarriersusedininhalationpowders[J]IntJPharm,2000196(1)95103[14]SrlchanaTMartinGPMarriottC.Ontherelationshipbetweendrugandcarrierdepositionfromdrypowderinhalersinvitro[J]IntJPharm1998167(1-2)13-23[15][J]200237(2)115-118[16]SrichanaTSuedeeRReanmongkolW.Cyclodextrinasapotentialdrugcarrierinsalbutamoldrypowderaerosolstheinvitrodepositionandtoxicitystudiesofthecomplexes[J].RespirMed200195(6)513-519[17]HartwigSteckel,LarsPichertandBerndW.Mller.InfluenceofprocessparametersintheASESprocessonparticlepropertiesofbudesonideforpulmonarydelivery.EuropeanJournalofPharmaceuticsandBiopharmaceutics,Volume57,Issue3,May2004,Pages507-512[18]YeoSLimGDebenedectiPGeta1Formationofmicroparticulatepowdersusingasupercriticalfluidantisolvent[J]BiotechnolBioeng199341341346[19]..200338(3)218222[20]NainiVByronPRPhillipsEMPhysicochemicalstabilityofcrystallinesugarsandtheirspray-driedforms:dependenceuponrelativehumidityandsuitabilityforuseinpowderinhalers[J]DrugDevIntPharm199824(10)895909[21][M]1998248[22]Cassidy0ECarterPARowleyGetalTriboelectrificationofspray-driedlactosepreparedfromdifferentfeed-stockconcentrations[J]JPharmPharmacol200052(1)1317[23]BennettFSCarterPARowleyGetalModificationofelectrostaticchargeoninhaledcarrierlactoseparticlesbyadditionoffineparticles[J].DrugDevIndPharm,1999,25(1)99-103[24]YoungPM,Price,TobynMJ,etal.Investigationintotheeffectofhumidityondrug-druginteractionsusingtheatomicforcemicroscope[J].PharmSci,2003,92(4):815-822.[25]DunbarC,ScheuchG,SommererKetal.Invitroandinvivodosedeliverycharacteristicsoflargeporousparticlesforinhalation[J].IntJPharm,2002,245(1-2):179-189.[26]NewhouseMT,HirstPH,DudduSP,etal.InhalationofadrypowdertobramycinPulmoSphereformulationinhealthyvolunteers[J].Chest,2003,124(1):360-366.[27]MaaYFNguyenPAAndyaJDetalEffectofspraydryingandsubsequentprocessingconditionsonresidualmoisturecontentandphysical/biochemicalstabilityofproteininhalationpowders[J]PharmRes199815(5)768-775.[28]FDAGuidanceforIndustryMeteredDoseInhaler(MDI)andDryPowderInhaler(DPI)DrugProductsChemistryManufacturingandControlDocumentation[EBOLlhttp//[29]C1arkeMJTobynMJStanidorthJNPhysicochemicalfactorsgoverningtheperformanceofnedocromilsodiumasadrypowderaeroso1[J]JPharmSci200089(9)1160-1169[30]PattonJSBukarJNagarajanSInhaledinsulin[J]AdvDrugDelivRev199935(23)235-247[31]deKoningJPvanderMarkTWCoenegrachtPMetalEffectofanexternalresistancetoaiflowontheinspiratoryflowcurve[J]IntJPharm2002234(1-2)257-266[32]NewmanSPBusseWWEvo1utionofdrypowdeinhalerdesignformulationandperformance[J].RespirMed200296(5)293-304[33]SumbyBSlaterAAtkinsPJetalReviewofdrypowderinhalers[J]AdvDrugDelivRev199726(1)51-58肺部给药新剂型-吸入粉雾剂作者：陈莹，李得馨，张悦作者单位：天津天士力集团化学制药研究所,天津300410本文链接：